35 results about "Macular disease" patented technology

Provided herein are methods and systems to screen for subjects at risk for retinal-associated eye diseases or to monitor the progression / regression thereof. Generally, the method comprises simultaneously or sequentially displaying to a potentially at-risk individual targets of parallel and nonparallel lines, obtaining an orientation discrimination threshold based on the subject's selections and correlating an increase in the threshold compared to that of a normal control or to a previous threshold measured for the subject as indicative of risk for a retinal-associated eye disease or a progression of the eye disease. Also provided are program storage devices and computer program products effective to store instructions or source code to perform the methods.

The invention aims to provide a composition with an effect of improving eyesight and a preparation thereof, and particularly provides a composition which takes black Chinese wolfberries and wolfberryfruits or extracts thereof as effective components and has the effect of improving eyesight. The composition provided by the invention combines the functions of relieving visual fatigue and achievingprevention and auxiliary treatment of eyesight problems such as failure of eyesight, nyctalopia, muscae volitantes, glaucoma and cataract caused by maculopathy, pigmented retinopathy and diabetic retinopathy, so that the eyesight can be improved to the maximum extent; and furthermore, from the traditional Chinese medicine theory, both the wolfberry fruits and the black Chinese wolfberries have theeffect of removing heat from the liver so as to improve eyesight.

The invention discloses an effect evaluation kit for anti-vascular endothelial growth factor drugs treating wet age-related macular degeneration diseases. The kit includes optional related reagents for detection of VEGFA gene rs943080 variation. The invention also discloses application of VEGFA gene rs943080 variation in preparation of effect evaluation reagents for anti-vascular endothelial growth factor drugs treating wet age-related macular degeneration diseases. The kit provided by the invention can evaluate the treatment effect of anti-vascular endothelial growth factor drugs on wet age-related macular degeneration diseases, and plays an important role in treatment of wet age-related macular diseases.

The invention discloses a method for constructing a classification model for segmenting macular lesion regions of fundus images, which comprises the following steps: selecting multiple fundus images, performing grayscale processing on them to obtain multiple grayscale images, and performing grayscale processing on the grayscale images Samples are obtained by sampling the foreground and background of the sample respectively; the transformation matrix is ​​obtained by using the generalized low-rank approximation method, and the dimensionality reduction process is performed on the sample based on the transformation matrix to obtain the low-rank approximation matrix of the sample; the low-rank approximation matrix of the sample is added to The label information is used as supervision to construct the manifold regularization item; the objective function is constructed by combining the generalized low-rank approximation method and the manifold regularization item, and the iterative optimization method is used to solve the objective function to obtain the optimal transformation matrix and the optimal low-rank approximation of the sample matrix; constructing a classification model based on the optimal low-rank approximate matrix and label information. The classification model of the present invention can extract feature descriptors that are both low-dimensional and highly distinguishable, and can improve segmentation accuracy.

Disclosed is an agent for inhibiting or reducing light sensitivity comprising a substance that inhibits or reduces ubiquitination, for example, an agent for inhibiting or reducing light sensitivity capable of protecting a retina, reducing retinal degeneration, reducing aging of a retina and / or reducing hyperesthesia. The present invention is suitable for use in amelioration or prevention of a symptom associated with light reception, such as age-related macular degeneration, retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease, cone-rod dystrophy, diabetic retinopathy, macular edema, retinal ischemia, photosensitive seizure, photosensitive epilepsy, psychiatric disorders, photic maculopathy, asthenopia, retinal dysfunction, sleep disorders, migraine and light-induced damage.

The invention relates to the field of biotechnology, and specifically discloses the application of a combination of small molecular compounds in the preparation of a medicament for preventing and treating retinal damage diseases. The combination of small molecule compounds can effectively antagonize cell death and dysfunction caused by oxidative stress on retinal pigment epithelial cells. It can effectively protect retinal pigment epithelial cells and thus protect the structural integrity and normal function of the entire retinal layer cells. It can be used for prevention and potential Treating retinal damage caused by oxidative stress is particularly beneficial for preventing and / or treating retinal damaging diseases such as age-related macular degeneration. In addition, the present invention verifies through experiments that the combination of small molecule compounds has no obvious pharmacological toxicity, and can effectively control the occurrence and development of retinal damage diseases, providing new opportunities for the development of the unknown biological activity of the combination of small molecule compounds and future clinical therapeutic effects. theoretical support.